Sign in
Not yet recruitingNo phase

Effect of tNGS on CAP Patients With Initial Treatment Failure

Key facts

Who runs it
Capital Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
524 people, planned
Started
10 Apr 2026
Expected to end
28 Feb 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Targeted next-generation sequencing
  • Conventional microbiological testing
  • Follow-up at Day 30
Record updated
16 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adults (age ≥ 18 years)
  • Diagnosed of community-acquired pneumonia
  • Initial treatment failure

Who cannot take part

  • Nasopharyngeal carcinoma currently receiving radiotherapy
  • tNGS or mNGS already performed on respiratory samples during the current illness
  • Suspected lung abscess or empyema
  • Cerebral infarction within the past three months
  • Dysphagia
  • Tracheostomy
  • Long-term bedridden patients (ADL score ≤ 60)
  • Pathogens identified within the past 7 days that adequately explain the current clinical presentation
  • Bronchiectasis with large amounts of sputum and documented bacterial detection within the past six months
  • Inability to obtain eligible respiratory samples
  • CURB-65 score ≤ 1
  • Expected discharge or death within 48 hours

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized controlled trial designed to evaluate the impact of tNGS in patients with community-acquired pneumonia who experience initial treatment failure.

The 2 groups in the trial

  • tNGS groupTreatment being tested

    Lower respiratory tract samples collected (BALF, sputum); undergo targeted next-generation sequencing in addition to conventional microbiological testing; follow-up by telephone on day 30 (D30).

    Treatment: Targeted next-generation sequencing, Conventional microbiological testing, and Follow-up at Day 30

  • Control groupExisting treatment, for comparison

    Lower respiratory tract samples collected (BALF, sputum); undergo conventional microbiological testing; follow-up by telephone on day 30 (D30).

    Treatment: Conventional microbiological testing and Follow-up at Day 30

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Targeted Next-generation Sequencing on Hospitalized Patients With Community-acquired Pneumonia and Initial Treatment Failure
Record updated
16 March 2026